Genscript Biotech Corporation
1548
Clasificación en acciones
#2100
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Precio por acción
$4.37
Última sincronización: 2026-10-21
Capitalización bursátil
$9.84B
Cambio (1 día)
2.30%
Cambio (1 año)
111.50%
País
HK
Comercio Genscript Biotech Corporation (1548)
Categoría
Healthcare
Ingresos de Genscript Biotech Corporation (1548)
Ingresos en Jun 2026 TTM: $844.00M
Según los últimos informes financieros de Genscript Biotech Corporation, los ingresos actuales de la empresa (TTM) son $844.00M. En 2023, la empresa obtuvo unos ingresos de $839.53M un aumento con respecto a los ingresos del año 2022, que fueron de $625.70M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Genscript Biotech Corporation desde 2013 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $844.00M | 41.97% |
| 2024 | $594.49M | -29.19% |
| 2023 | $839.53M | 34.17% |
| 2022 | $625.70M | 27.67% |
| 2021 | $490.10M | 25.39% |
| 2020 | $390.85M | 42.98% |
| 2019 | $273.35M | 18.33% |
| 2018 | $231.02M | 51.34% |
| 2017 | $152.65M | 33.04% |
| 2016 | $114.74M | 32.32% |
| 2015 | $86.71M | 23.88% |
| 2014 | $69.99M | 16.45% |
| 2013 | $60.10M | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | 1,395.77% |
US
|
|
| $2.23B | 163.98% |
US
|
|
| $15.74B | 1,765.44% |
AU
|
|
| $6.02B | 613.42% |
NL
|
|
| - | - |
CH
|
